8-K: Indivior Reports Record SUBLOCADE Revenue, $400M Buyback

Indivior Pharmaceuticals, Inc. announced record SUBLOCADE revenue and adjusted EBITDA for Q4 and full-year 2025, alongside a new $400 million share repurchase program and reaffirmed 2026 guidance.

Summary

• Record total SUBLOCADE net revenue of $252 million for Q4 2025, representing a 30% increase year-over-year.
• Record total SUBLOCADE net revenue of $856 million for full-year 2025, up 13% year-over-year.
• GAAP net income for full-year 2025 was $210 million, a significant increase from $7 million in FY 2024.
• Adjusted EBITDA reached $142 million for Q4 2025 (up 91% YoY) and $428 million for full-year 2025 (up 20% YoY).
• Completed Phase I of the Indivior Action Agenda, 'Generate Momentum,' and commenced Phase II, 'Accelerate,' on January 1, 2026.
• Authorized a new share repurchase program of up to $400 million with a term of up to 18 months.
• Reaffirmed full-year 2026 financial guidance, projecting total net revenue between $1,125 million and $1,195 million and Adjusted EBITDA between $535 million and $575 million.
• Successfully concluded the legacy U.S. Department of Justice (DOJ) matter by paying the outstanding $295 million obligation on November 20, 2025.
• Completed redomiciliation from the United Kingdom to the United States on January 26, 2026, establishing Indivior Pharmaceuticals, Inc. as the new parent company.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by robust SUBLOCADE performance, significant profitability improvements, strategic operational streamlining, and a clear, well-defined future growth agenda supported by a substantial share repurchase program.

Positives

• Record SUBLOCADE net revenue for Q4 2025 ($252 million, +30% YoY) and FY 2025 ($856 million, +13% YoY) demonstrates strong product growth.
• Significant increase in GAAP net income for FY 2025 to $210 million from $7 million in FY 2024, indicating improved profitability.
• Adjusted EBITDA grew substantially, with Q4 2025 at $142 million (+91% YoY) and FY 2025 at $428 million (+20% YoY), reflecting operational efficiencies.
• Adjusted EBITDA margin expanded by 15 percentage points in Q4 2025 and 5 percentage points in FY 2025.
• Successful completion of Phase I of the Indivior Action Agenda and the initiation of Phase II 'Accelerate' provides a clear strategic direction.
• Launch of a nationwide direct-to-consumer (DTC) campaign for SUBLOCADE shows positive early indicators, including increased patient awareness (44% in Q425 vs. 15% in Q125) and online search volume (+60% in Q425 vs. Q325).
• Resolution of the legacy U.S. Department of Justice (DOJ) matter removes a significant financial and legal overhang.
• Redomiciliation to the United States simplifies the corporate structure and may enhance investor appeal.
• Authorization of a new $400 million share repurchase program signals confidence in future cash flow and commitment to shareholder returns.
• Strong 2026 financial guidance projects mid-teens SUBLOCADE dispense unit growth and a 30% increase in Adjusted EBITDA at the midpoint.
• A low leverage ratio of 0.7x as of December 31, 2025, indicates a healthy financial position.
• SUBLOCADE benefits from significant intellectual property protection extending to 2031-2038, with additional patents pursued to 2035-2044.

Negatives

• Cash and investments decreased to $222 million at December 31, 2025, from $347 million at December 31, 2024, primarily due to the $295 million DOJ payment.
• GAAP gross margin decreased by 300 basis points in Q4 2025 (81% vs 84%) and 51 basis points in FY 2025 (80% vs 81%).
• Total Net Revenue guidance for 2026 ($1,125 million $1,195 million) represents a -6% year-over-year change at the midpoint compared to FY 2025 actuals ($1,239 million), indicating a projected decline in overall revenue likely due to product discontinuations.

Risks

• Lower than expected future sales of products.
• Greater than expected impacts from competition.
• Unanticipated costs, including the effects of potential tariffs and retaliatory tariffs.
• Inability to identify efficiencies and fund additional investments expected to generate increased revenue.
• Market acceptance of long-acting injectables.
• Cash available for future share repurchases and the market price of common stock in the future.
• Ability to identify accretive investment opportunities, negotiate with third parties to acquire such assets, and efficiently manage such assets and execute upon opportunities.
• Results of pending and future clinical trials.
• Decisions of relevant regulators.

Future Outlook

Indivior is now executing Phase II of its 'Accelerate' agenda, targeting mid-teens SUBLOCADE dispense unit growth and a faster acceleration of adjusted EBITDA and cash flow throughout 2026. The company reaffirmed its full-year 2026 financial guidance, projecting total net revenue between $1,125 million and $1,195 million and Adjusted EBITDA between $535 million and $575 million. Strategic capital deployment will prioritize debt management, opportunistic share repurchases, and evaluating business development opportunities to progress towards Phase III 'Breakout' in the second half of 2026 and beyond.

Management Comments

• "In 2025 we successfully completed Phase I of the Indivior Action Agenda – Generate Momentum. We sharpened our focus on our highest growth opportunity, U.S. SUBLOCADE, established our go-forward operating model and strengthened our financial profile. We are now executing Phase II of the Indivior Action Agenda – Accelerate, which includes accelerating SUBLOCADE throughout 2026 and immediately accelerating adjusted EBITDA and cash flow at a faster rate. We expect our increased cash flow will enable us to strategically deploy capital to create value for our shareholders." Joe Ciaffoni, Chief Executive Officer.
• "We delivered on our financial commitments in 2025, growing total SUBLOCADE net revenue 13% and adjusted EBITDA 20%, while positioning Indivior for acceleration in 2026. In 2026, we expect to deliver SUBLOCADE dispense unit growth in the mid-teens with operating expenses that will not exceed $450 million, and generate approximately $300 million in cash flow from operations. Our capital deployment priorities include managing our debt, opportunistically deploying our new $400 million share repurchase program and evaluating business development opportunities as we earn our way to Phase III of the Indivior Action Agenda – Breakout." Ryan Preblick, Chief Financial Officer.

Industry Context

StockSavvy.ai notes that Indivior's sharpened focus on SUBLOCADE, a long-acting injectable (LAI) for opioid use disorder (OUD), aligns with a broader industry trend towards more effective and patient-centric treatment modalities in addiction medicine. The company's direct-to-consumer campaign and efforts to expand LAI penetration in the buprenorphine medication-assisted treatment (BMAT) category address a significant unmet need in the OUD market, where only a fraction of diagnosed patients receive BMAT and LAI usage is still relatively low (estimated ~8.5% of the BMAT population). The expectation among healthcare professionals for LAI usage to increase to 20-30% of the BMAT population suggests a favorable market shift for SUBLOCADE and other LAI treatments.

Comparison to Industry Standards

• Indivior's SUBLOCADE is positioned as the #1 prescribed, first-in-class, monthly subcutaneous long-acting injectable (LAI) medication for moderate to severe OUD.
• The company boasts over 20 years of leadership in OUD treatment, having treated over 475,000 patients, demonstrating a strong legacy and market presence.
• Healthcare professionals (HCPs) anticipate LAI usage to increase to 20-30% of the BMAT population, indicating a substantial growth opportunity for SUBLOCADE within its market segment, outperforming current penetration rates.
• SUBLOCADE benefits from broad payor access, with approximately 88% coverage in Medicaid and Commercial plans, and 95% of participants in the copay program paying $0, which is a strong competitive advantage in ensuring patient access compared to less accessible treatments.

Corporate Governance

Legal Proceedings

• Concluded the legacy U.S. Department of Justice (DOJ) matter on November 20, 2025, by paying in full the outstanding obligation of $295 million associated with the matter.

Stakeholder Impact

• Shareholders: Expected to benefit from strong financial performance, increased profitability, a new $400 million share repurchase program, and a clear strategy for future growth and value creation. The U.S. redomiciliation may improve investor access and liquidity.
• Patients: Continued focus on SUBLOCADE and pipeline development for Opioid Use Disorder (OUD) aims to provide more effective and accessible treatment options, supported by patient education campaigns.
• Employees: Organizational simplification and transformation of the operating model may involve some restructuring, but the overall focus on growth and acceleration could provide stability and new opportunities.
• Creditors: Debt management is a capital deployment priority, and the company's low leverage ratio (0.7x) indicates a healthy financial position, enhancing creditworthiness.

Next Steps

• Accelerate U.S. SUBLOCADE dispense unit and net revenue throughout 2026.
• Immediately accelerate adjusted EBITDA and cash flow at a faster rate in 2026.
• Strategically deploy capital to manage debt, opportunistically repurchase shares, and evaluate business development opportunities.
• Progress towards Phase III of the Indivior Action Agenda, 'Breakout,' in H2 2026 and beyond, to acquire next growth drivers.
• Continue to invest in SUBLOCADE at sustained levels.
• Advance state and federal policies that support durable access to increase long-term adoption of LAIs.
• Activate advocates to accelerate access, reduce system barriers, and increase awareness.
• Strengthen field force messaging and productivity and improve commercial channel dispense yield.
• Drive awareness of the updated SUBLOCADE label and unique rapid initiation.

Key Dates

Recommendation

The filing demonstrates robust financial performance, particularly with SUBLOCADE revenue and Adjusted EBITDA growth significantly exceeding prior year results. The successful completion of Phase I of the 'Indivior Action Agenda' and the clear strategic roadmap for Phase II 'Accelerate' in 2026, including mid-teens SUBLOCADE dispense unit growth and a 30% increase in Adjusted EBITDA, signal strong future profitability. The new $400 million share repurchase program underscores management's confidence and commitment to shareholder value. Furthermore, the resolution of the legacy DOJ matter and the redomiciliation to the U.S. remove significant overhangs and simplify the corporate structure, making the company more attractive to U.S. investors. The strong IP protection for SUBLOCADE and the pipeline for OUD treatments provide a solid foundation for sustained growth in a critical therapeutic area.

Keywords

Indivior, INDV, SUBLOCADE, Opioid Use Disorder, OUD, Pharmaceuticals, Financial Results, Earnings, Adjusted EBITDA, Share Repurchase, Corporate Governance, Redomiciliation, SEC Filing, 8-K, Q4 2025, FY 2025, 2026 Guidance, Long-Acting Injectable, LAI, Buprenorphine